Samareh Azeredo Da Silveira

Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a virtual incubator dedicated to the identification of discovery-stage pharmaceuticals and diagnostics. Since then, she focused on the development of breakthrough technologies in the fields of critical care and infectious diseases. From 2011 to 2018, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO, where she outlicensed a sepsis diagnostic technology to several industrial partners. She holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL), and authored numerous publications and opinion reviews.